ArticleMagma (New York, N.Y.)2022
Mapping tumour heterogeneity with pulsed 3D CEST MRI in non-enhancing glioma at 3 T.
Article in Magma (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Amide proton transfer-weighted CEST MRI for radiotherapy target delineation of glioblastoma: a prospective pilot study.European radiology experimental · 2024Trial
- Hypoxia-targeted BOLD MRI signal heterogeneity as a complementary metric for glioblastoma characterization: a pilot study.Journal of neuro-oncology · 2026Article
- Chemical Exchange Saturation Transfer Imaging in Neuroinflammation: Methods, Challenges, and Recommendations.International journal of molecular sciences · 2025Review
- Advances in diffuse glioma assessment: preoperative and postoperative applications of chemical exchange saturation transfer.Frontiers in neuroscience · 2024Review
- Imaging Role in Diagnosis, Prognosis, and Treatment Response Prediction Associated with High-grade Glioma.Journal of medical signals and sensors · 2024Review
- Reproducibility of APT-weighted CEST-MRI at 3T in healthy brain and tumor across sessions and scanners.Scientific reports · 2023Article
- Hierarchical K-means clustering method for accelerated Lorentzian estimation (KALE) in chemical exchange saturation transfer-magnetic resonance imaging quantification.Quantitative imaging in medicine and surgery · 2023Article
- Advanced MR Techniques for Preoperative Glioma Characterization: Part 2.Journal of magnetic resonance imaging : JMRI · 2023Review
- Pre-contrast MAGiC in treated gliomas: a pilot study of quantitative MRI.Scientific reports · 2022Article
- Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: Application to brain tumors.Magnetic resonance in medicine · 2022Review
- Lorentzian-Corrected Apparent Exchange-Dependent Relaxation (LAREX) Ω-Plot Analysis-An Adaptation for qCEST in a Multi-Pool System: Comprehensive In Silico, In Situ, and In Vivo Studies.International journal of molecular sciences · 2022Article
- Molecular Imaging of Brain Tumors and Drug Delivery Using CEST MRI: Promises and Challenges.Pharmaceutics · 2022Review
- 3D APT and NOE CEST-MRI of healthy volunteers and patients with non-enhancing glioma at 3 T.Magma (New York, N.Y.) · 2022Article
- Use of multimodality imaging, histology, and treatment feasibility to characterize a transgenicFrontiers in oncology · 2022Article
- Advanced Imaging Techniques for Newly Diagnosed and Recurrent Gliomas.Frontiers in neuroscience · 2022Review
- Chemical Exchange Saturation Transfer MRI: What Neuro-Oncology Clinicians Need To Know.Technology in cancer research & treatmentReview
- Advanced Imaging and Computational Techniques for the Diagnostic and Prognostic Assessment of Malignant Gliomas.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
objectiveAmide proton transfer (APT) weighted chemical exchange saturation transfer (CEST) imaging is increasingly used to investigate high-grade, enhancing brain tumours. Non-enhancing glioma is currently less studied, but shows heterogeneous pathophysiology with subtypes having equally poor prognosis as enhancing glioma. Here, we investigate the use of CEST MRI to best differentiate non-enhancing glioma from healthy tissue and image tumour heterogeneity. MATERIALS &
methodsA 3D pulsed CEST sequence was applied at 3 Tesla with whole tumour coverage and 31 off-resonance frequencies (+6 to -6 ppm) in 18 patients with non-enhancing glioma. Magnetisation transfer ratio asymmetry (MTRasym) and Lorentzian difference (LD) maps at 3.5 ppm were compared for differentiation of tumour versus normal appearing white matter. Heterogeneity was mapped by calculating volume percentages of the tumour showing hyperintense APT-weighted signal.
resultsLDamide gave greater effect sizes than MTRasym to differentiate non-enhancing glioma from normal appearing white matter. On average, 17.9 % ± 13.3 % (min-max: 2.4 %-54.5 %) of the tumour volume showed hyperintense LDamide in non-enhancing glioma.
conclusionThis works illustrates the need for whole tumour coverage to investigate heterogeneity in increased APT-weighted CEST signal in non-enhancing glioma. Future work should investigate whether targeting hyperintense LDamide regions for biopsies improves diagnosis of non-enhancing glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.